Tag Archives: traction

Roche’s Tecentriq nabs a solo OK in first-line lung cancer. But will it gain traction?

It was a long run, but Merck’s Keytruda finally has some company in the previously untreated non-small cell lung cancer monotherapy department. Whether that company represents any real threat to its market share, however, remains to be seen. The FDA Monday green-lighted Roche’s Tecentriq on its own for newly diagnosed, metastatic patients without EGFR or… Read More »